Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Director | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.64 · Expires 2036-02-20 | Direct | 12,050 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 12,050 · Balance 12,050 F1: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
89bio, Inc.
Report date October 30, 2025 · Filed October 30, 2025
Section 16 reporting ended · disclosed 2025-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 934,273 |
Reported balance
After 2025-10-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-10-30 · Grant · Acquired 125,000 · Balance 934,273 F1: Represents settlement by the Issuer of performance-based restricted stock units granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on September 9, 2022 and February 1, 2024, which vested as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger (as defined below), pursuant to the Merger Agreement (as defined below). F2: Includes an aggregate of 1,203 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on October 22, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-10-30 · Other · Disposed 934,273 · Balance 0 F3: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, [continues to Footnote 4] F4: [continues from Footnote 3] subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. In addition, as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit or performance-based restricted stock unit became fully vested and was cancelled in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2028-11-09 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-30 · Disposition to issuer · Disposed 120,231 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.11 · Expires 2029-07-30 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-30 · Disposition to issuer · Disposed 132,242 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.50 · Expires 2030-02-14 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-30 · Disposition to issuer · Disposed 170,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.01 · Expires 2031-02-05 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-30 · Disposition to issuer · Disposed 203,750 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.44 · Expires 2032-02-16 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-30 · Disposition to issuer · Disposed 220,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.70 · Expires 2033-02-09 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-10-30 · Disposition to issuer · Disposed 300,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-10-30 · Disposition to issuer · Disposed 605,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.60 · Expires 2035-02-01 | Direct | 0 |
Reported balance
After 2025-10-30 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-10-30 · Disposition to issuer · Disposed 848,000 · Balance 0 F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents settlement by the Issuer of performance-based restricted stock units granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on September 9, 2022 and February 1, 2024, which vested as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger (as defined below), pursuant to the Merger Agreement (as defined below).
F2: Includes an aggregate of 1,203 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on October 22, 2025.
F3: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, [continues to Footnote 4]
F4: [continues from Footnote 3] subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. In addition, as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit or performance-based restricted stock unit became fully vested and was cancelled in exchange for the right to receive the Offer Price.
F5: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6]
F6: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7]
F7: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 24, 2026 18:48 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001628280-26-011325 · wk-form4_1771976881.xml · derivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2036-02-20 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 848,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 10 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 848,000 shares Expires 2035-02-01 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 605,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 9 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 605,000 shares Expires 2034-02-01 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 8 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2033-02-09 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 7 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 220,000 shares Expires 2032-02-16 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 203,750 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 6 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 203,750 shares Expires 2031-02-05 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $32.50 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 5 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2030-02-14 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 132,242 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 4 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,242 shares Expires 2029-07-30 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | Disposition to issuerStock Option (Right to Buy) · Derivative | 120,231 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · derivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,231 shares Expires 2028-11-09 F5 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 7] F7 · derivative.exercise_date: [Continues from Footnote 6] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | OtherCommon Stock | 934,273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, [continues to Footnote 4] F4 · shares: [continues from Footnote 3] subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. In addition, as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit or performance-based restricted stock unit became fully vested and was cancelled in exchange for the right to receive the Offer Price. F3 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, [continues to Footnote 4] F4 · price: [continues from Footnote 3] subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement") (the Closing Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. In addition, as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit or performance-based restricted stock unit became fully vested and was cancelled in exchange for the right to receive the Offer Price. Read SEC document |
| October 30, 2025 Filed Oct 30, 2025 20:22 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-259054 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 934,273 F1 · shares: Represents settlement by the Issuer of performance-based restricted stock units granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on September 9, 2022 and February 1, 2024, which vested as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger (as defined below), pursuant to the Merger Agreement (as defined below). F1 · balance_after: Represents settlement by the Issuer of performance-based restricted stock units granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on September 9, 2022 and February 1, 2024, which vested as of immediately prior to and conditioned upon the occurrence of the effective time of the Merger (as defined below), pursuant to the Merger Agreement (as defined below). F2 · balance_after: Includes an aggregate of 1,203 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on October 22, 2025. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:06 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 55,836 | $9.16 | $511,457.76 |
DisclosureSEC source: 0000950170-25-103374 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,070 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. F2 · balance_after: Includes an aggregate of 1,666 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 12:06 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,050 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001404644-25-000066 · wk-form4_1749830797.xml · derivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,050 Underlying: Common Stock · 12,050 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 17, 2025 Filed Feb 19, 2025 16:01 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 3,249 | $10.57 | $34,341.93 |
DisclosureSEC source: 0000950170-25-023119 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 862,240 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. F2 · balance_after: Includes an aggregate of 797 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| February 09, 2025 Filed Feb 11, 2025 16:01 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 8,946 | $11.41 | $102,073.86 |
DisclosureSEC source: 0000950170-25-017866 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,692 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:32 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 848,000 | $0.00 Strike: $9.60 | $0.00 |
DisclosureSEC source: 0000950170-25-014088 · ownership.xml · derivative · entry 4 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848,000 Underlying: Common Stock · 848,000 shares Expires 2035-02-01 F4 · derivative.exercise_date: Represents a right to purchase a total of 848,000 shares of the Issuer's Common Stock, one quarter of which will vest on February 1, 2026, with the remaining three quarters vesting in equal quarterly installments over the following three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:32 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 9,598 | $9.60 | $92,140.80 |
DisclosureSEC source: 0000950170-25-014088 · ownership.xml · nonDerivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 873,638 F3 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:32 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014088 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 883,236 F2 · kind: Represents restricted stock units that vest in equal semi-annual installments over two years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:32 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 212,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014088 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 683,236 F1 · kind: Represents restricted stock units that vest in equal semi-annual installments over three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 06:02 UTC | 89bio, Inc. ETNB · Entity 73682 | PurchaseCommon Stock | 5,000 | $7.89 | $39,450.00 |
DisclosureSEC source: 0000950170-24-134750 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,236 Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 06:05 UTC | 89bio, Inc. ETNB · Entity 73682 | PurchaseCommon Stock | 10,000 | $8.35 | $83,500.00 |
DisclosureSEC source: 0000950170-24-130418 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,236 Read SEC document |
| August 17, 2024 Filed Aug 19, 2024 17:29 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 4,601 | $8.04 | $36,992.04 |
DisclosureSEC source: 0000950170-24-098698 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 456,236 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. F2 · balance_after: Includes an aggregate of 1,666 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on June 28, 2024. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 14:37 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 7,700 | $0.00 Strike: $42.59 | $0.00 |
DisclosureSEC source: 0001404644-24-000070 · wk-form4_1718649414.xml · derivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2034-06-14 F1 · derivative.exercise_date: This option represents a right to purchase 7,700 shares of the Issuer's common stock, which will vest in its entirety on the earlier of (a) the first anniversary of the date of grant or (b) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such applicable vesting date. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:01 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000950170-24-041024 · ownership.xml · derivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,231 Underlying: Common Stock · 25,000 shares Expires 2028-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is vested in full. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:01 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 52,718 | $10.91 | $575,153.38 |
DisclosureSEC source: 0000950170-24-041024 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,171 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on July 5, 2023. F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.65 to $11.54. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:01 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionCommon Stock | 25,000 | $1.93 | $48,250.00 |
DisclosureSEC source: 0000950170-24-041024 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 511,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 18:43 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 4,477 | $10.76 | $48,172.52 |
DisclosureSEC source: 0000950170-24-022433 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 486,889 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on July 5, 2023. Read SEC document |
| February 17, 2024 Filed Feb 23, 2024 20:51 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 4,602 | $9.74 | $44,823.48 |
DisclosureSEC source: 0000950170-24-019662 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491,366 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. F2 · balance_after: Due to an administrative error, the exercise of an aggregate of 15,000 options was erroneously omitted from the Form 4 filed by the Reporting Person on March 27, 2023. This form reflects the correct amount of common stock owned by the Reporting Person. The exercise of an aggregate of 15,000 options was reported in Table II on the Form 4 filed by the Reporting Person on June 7, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 20:58 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 12,670 | $8.45 | $107,061.50 |
DisclosureSEC source: 0000950170-24-014886 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,968 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. Read SEC document |
| February 05, 2024 Filed Feb 5, 2024 20:16 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 5,068 | $9.80 | $49,666.40 |
DisclosureSEC source: 0000950170-24-011475 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,646 F2 · shares: These shares were withheld from the vesting of a performance-based RSU award to cover the estimated tax withholding obligation. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 20:16 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 605,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0000950170-24-011475 · ownership.xml · derivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 605,000 Underlying: Common Stock · 605,000 shares Expires 2034-02-01 F3 · derivative.exercise_date: This option represents a right to purchase a total of 605,000 shares of the Issuer's Common Stock, one quarter of which will vest on February 1, 2025, with the remaining three quarters vesting in equal quarterly installments over the following three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 20:16 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011475 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,714 F1 · kind: Represents restricted stock units ("RSUs") that vest in equal semi-annual installments over three years, subject to the Reporting Person's continued service to the Issuer. F1 · shares: Represents restricted stock units ("RSUs") that vest in equal semi-annual installments over three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 18:58 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,400 | $0.00 Strike: $32.30 | $0.00 |
DisclosureSEC source: 0000950170-24-005539 · ownership.xml · derivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,400 Underlying: Common Stock · 15,400 shares Expires 2034-01-16 F1 · derivative.exercise_date: This option represents the right to purchase 15,400 shares of common stock of the Issuer, and vests in equal monthly installments through January 16, 2027, subject to the reporting person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:31 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 27,511 | $11.53 | $317,201.83 |
DisclosureSEC source: 0000950170-24-003105 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,714 F2 · shares: These shares were withheld from the vesting of a performance-based RSU award to cover the estimated tax withholding obligation. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 18:31 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003105 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,225 F1 · shares: Represents settlement by the Issuer of performance-based restricted stock units ("RSUs") granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on September 9, 2022, which vested based on the Issuer's achievement of corporate performance objectives. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 16:54 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000950170-24-001035 · ownership.xml · derivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,231 Underlying: Common Stock · 50,000 shares Expires 2028-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is vested in full. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 16:54 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 50,000 | $11.20 | $560,000.00 |
DisclosureSEC source: 0000950170-24-001035 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,225 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on July 5, 2023. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.035 to $11.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 16:54 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionCommon Stock | 50,000 | $1.93 | $96,500.00 |
DisclosureSEC source: 0000950170-24-001035 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 351,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 275 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on December 31, 2023. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 17:49 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 4,501 | $15.46 | $69,585.46 |
DisclosureSEC source: 0000899243-23-018332 · doc4.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,950 F1 · shares: These shares were withheld from the vesting of restricted stock units to cover the estimated tax withholding obligation. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:39 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 16,527 | $18.95 | $313,186.65 |
DisclosureSEC source: 0000950170-23-031839 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,451 F3 · shares: These shares were withheld from the vesting of a performance-based RSU award to cover the estimated tax withholding obligation. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:39 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 33,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-031839 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,978 F1 · shares: Represents settlement by the Issuer of performance-based restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's Amended and Restated 2019 Equity Incentive Plan on February 17, 2022, which vested based on the Issuer's achievement of corporate performance objectives. F2 · balance_after: Includes an aggregate of 1,666 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 16:27 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-23-035866 · doc4.xml · derivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 17:04 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0000950170-23-026845 · ownership.xml · derivative · entry 3 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,231 Underlying: Common Stock · 15,000 shares Expires 2028-11-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is vested in full. F4 · balance_after: Due to an administrative error, the exercise of an aggregate of 15,000 options was erroneously omitted from the Form 4 filed by the Reporting Person on March 27, 2023. This form reflects the correct amount of stock options owned by the Reporting Person. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 17:04 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0000950170-23-026845 · ownership.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,978 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 17:04 UTC | 89bio, Inc. ETNB · Entity 73682 | Exercise / conversionCommon Stock | 15,000 | $1.93 | $28,950.00 |
DisclosureSEC source: 0000950170-23-026845 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 8 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 16:18 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 15,443 | $15.23 | $235,196.89 |
DisclosureSEC source: 0000899243-23-010403 · doc4.xml · nonDerivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,970 F2 · shares: These shares were withheld from the vesting of a performance-based RSU award to cover the estimated tax withholding obligation. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 16:18 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantCommon Stock | 33,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010403 · doc4.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,413 F1 · shares: Represents settlement by the Issuer of performance-based restricted stock units ("RSUs") granted to the Reporting Person under the Company's Amended and Restated 2019 Equity Incentive Plan on February 17, 2022, which vested based on the Issuer's achievement of corporate performance objectives. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 19:18 UTC | 89bio, Inc. ETNB · Entity 73682 | SaleCommon Stock | 15,000 | $16.00 | $240,000.00 |
DisclosureSEC source: 0000950170-23-010075 · ownership.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,080 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022. F2 · balance_after: Includes an aggregate of 8 shares acquired by the Reporting Person under the Issuer's 2019 Employee Stock Purchase Plan on December 30, 2022. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 18:38 UTC | 89bio, Inc. ETNB · Entity 73682 | Tax withholdingCommon Stock | 6,279 | $13.97 | $87,717.63 |
DisclosureSEC source: 0000899243-23-005875 · doc4.xml · nonDerivative · entry 1 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,072 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 17,886 restricted stock units on February 17, 2023. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 17:42 UTC | 89bio, Inc. ETNB · Entity 73682 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $14.70 | $0.00 |
DisclosureSEC source: 0000899243-23-004813 · doc4.xml · derivative · entry 2 PALEKAR ROHAN · CIK 0001423327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-02-09 F2 · derivative.exercise_date: This option represents a right to purchase a total of 300,000 shares of the Issuer's Common Stock, one quarter of which will vest on February 9, 2024, with the remaining three quarters vesting in equal quarterly installments over the following three years, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.